Eli Lilly Veteran Brings Record of Manufacturing Transformation,
Excellence
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme
Corporation (NASDAQ: GENZ) announced today that Scott Canute, the
former manufacturing head at Eli Lilly & Company and a respected leader
in the field, joined the company as President of Global Manufacturing
and Corporate Operations. In this position, Mr. Canute will oversee the
production of a diverse range of products manufactured at 17 sites
around the world.
“He is widely respected for transforming
manufacturing operations at Lilly and establishing its programs as a
standard for the industry. His experience will accelerate efforts to
strengthen our manufacturing sites, and consistently meet world-class
standards.”
“Scott Canute is among the very top people in the pharmaceutical
manufacturing field,” said Henri A. Termeer, Genzyme’s chairman and
chief executive officer. “He is widely respected for transforming
manufacturing operations at Lilly and establishing its programs as a
standard for the industry. His experience will accelerate efforts to
strengthen our manufacturing sites, and consistently meet world-class
standards.”
“I am very excited to be joining Genzyme, which clearly has such a
strong history of innovation and excellence,” said Scott Canute. “I look
forward to helping the company achieve the manufacturing capabilities
that are necessary to fully serve the patients that depend on our
products - both now and in the future.”
Last month, Genzyme also announced that Ron Branning, a leader in the
field of product quality, joined the company as Senior Vice President of
Global Product Quality. The hiring of new leadership in Manufacturing
and Quality is part of Genzyme’s comprehensive plan to strengthen its
global manufacturing operations.
Mr. Canute held progressively responsible positions at Lilly, ultimately
becoming President of Global Manufacturing Operations. In this role, he
directed all manufacturing and supply chain activities for the company’s
operations, which spanned 24 global manufacturing sites and more than 80
contract manufacturing operations. Mr. Canute oversaw operations that
included more than 14,000 employees, and that supplied product to more
than 140 countries. He also has experience with a variety of
technologies, including biologics, small and large molecules, and
devices.
During his 25-year career, he has resolved significant challenges,
including FDA warning letters and 483 post-inspection letters. He has
also managed multiple product launches and the development of new
manufacturing sites. During his tenure, Lilly’s manufacturing training
programs became models in the industry.
Mr. Canute holds a degree in chemical engineering from the University of
Michigan, and a masters in business administration from Harvard Business
School. He was also a National Association of Manufacturers board
member. In 2007, Mr. Canute left Lilly to pursue educational interests
in business leadership and ethics.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated
to making a major positive impact on the lives of people with serious
diseases. Since 1981, the company has grown from a small start-up to a
diversified enterprise with more than 12,000 employees in locations
spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in
approximately 100 countries, Genzyme is a leader in the effort to
develop and apply the most advanced technologies in the life sciences.
The company's products and services are focused on rare inherited
disorders, kidney disease, orthopaedics, cancer, transplant and immune
disease, and diagnostic testing. Genzyme's commitment to innovation
continues today with a substantial development program focused on these
fields, as well as cardiovascular disease, neurodegenerative diseases,
and other areas of unmet medical need.
Genzyme® is a registered trademark of Genzyme Corporation.
All rights reserved.
Genzyme’s press releases and other company information are available at www.genzyme.com
and by calling Genzyme’s investor information line at 1-800-905-4369
within the United States or 1-678-999-4572 outside the United States.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6165444&lang=en